
Frontline Eftilagimod Alpha/Pembrolizumab Yields Favorable OS in PD-L1–Negative HNSCC
Updated data from cohort B of the randomized phase 2b TACTI-003/KEYNOTE-C34 trial (NCT04811027) showed a median overall survival (OS) of 17.6 months alongside clinically meaningful responses with first-line eftilagimod alpha (IMP321) plus pembrolizumab …